Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Significance analysis of prognostic signatures.

Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, Schroeder MS, Risch T, Quackenbush J, Haibe-Kains B.

PLoS Comput Biol. 2013;9(1):e1002875. doi: 10.1371/journal.pcbi.1002875. Epub 2013 Jan 24.

2.

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M.

Breast Cancer Res. 2008;10(4):R65. doi: 10.1186/bcr2124. Epub 2008 Jul 28.

3.

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.

Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM.

BMC Med Genomics. 2011 Jan 9;4:3. doi: 10.1186/1755-8794-4-3.

4.

Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.

Huang CC, Tu SH, Lien HH, Huang CS, Huang CJ, Lai LC, Tsai MH, Chuang EY.

Breast Cancer Res Treat. 2014 Sep;147(2):353-70. doi: 10.1007/s10549-014-3104-6. Epub 2014 Aug 27.

PMID:
25158930
5.

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. Retraction in: Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. JAMA. 2012 Feb 1;307(5):453.

PMID:
18387932
6.

The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome.

Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Krüger S, Bruch HP, Auer G, Guo NL, Ried T.

Int J Cancer. 2009 Apr 1;124(7):1552-64. doi: 10.1002/ijc.24017.

7.
8.

Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer.

Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, Wang XV, Ahmadifar M, Tyekucheva S, Bernau C, Risch T, Ganzfried BF, Huttenhower C, Birrer M, Parmigiani G.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju049. doi: 10.1093/jnci/dju049. Review.

9.

The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer.

Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, Koritzinsky M, Kasprzyk A, Boutros PC, Wouters BG, Lambin P.

Radiother Oncol. 2012 Mar;102(3):436-43. doi: 10.1016/j.radonc.2012.02.002. Epub 2012 Feb 20.

10.

Pathway-based classification of cancer subtypes.

Kim S, Kon M, DeLisi C.

Biol Direct. 2012 Jul 3;7:21. doi: 10.1186/1745-6150-7-21.

11.

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Laas E, Mallon P, Duhoux FP, Hamidouche A, Rouzier R, Reyal F.

PLoS One. 2016 Feb 19;11(2):e0148957. doi: 10.1371/journal.pone.0148957. eCollection 2016.

12.

Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.

Nuyten DS, Hastie T, Chi JT, Chang HY, van de Vijver MJ.

Eur J Cancer. 2008 Oct;44(15):2319-29. doi: 10.1016/j.ejca.2008.07.015. Epub 2008 Aug 18.

13.

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.

Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF.

Breast Cancer Res. 2008;10(6):R93. doi: 10.1186/bcr2192. Epub 2008 Nov 13.

14.

Prognostic immune-related gene models for breast cancer: a pooled analysis.

Zhao J, Wang Y, Lao Z, Liang S, Hou J, Yu Y, Yao H, You N, Chen K.

Onco Targets Ther. 2017 Sep 11;10:4423-4433. doi: 10.2147/OTT.S144015. eCollection 2017.

15.

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer.

Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M, Klijn JG, Wang Y, Foekens JA.

BMC Cancer. 2007 Sep 25;7:182.

16.

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.

Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY.

PLoS One. 2012;7(9):e45831. doi: 10.1371/journal.pone.0045831. Epub 2012 Sep 25.

17.

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.

Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753. Epub 2010 Oct 14.

18.

A gene sets approach for identifying prognostic gene signatures for outcome prediction.

Kim SY, Kim YS.

BMC Genomics. 2008 Apr 16;9:177. doi: 10.1186/1471-2164-9-177.

19.

Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures.

Chen J, Sam L, Huang Y, Lee Y, Li J, Liu Y, Xing HR, Lussier YA.

J Biomed Inform. 2010 Jun;43(3):385-96. doi: 10.1016/j.jbi.2010.03.009. Epub 2010 Mar 27.

20.

Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.

Martin KJ, Patrick DR, Bissell MJ, Fournier MV.

PLoS One. 2008 Aug 20;3(8):e2994. doi: 10.1371/journal.pone.0002994.

Supplemental Content

Support Center